5-methyl-1-(1'-naphthyl)-2(1H)pyridone | 53427-82-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-methyl-1-(1'-naphthyl)-2(1H)pyridone
• 英文别名: 5-methyl-l-(1'-naphthyl)-2-(1H) pyridone；5-Methyl-1-(1-naphthyl)-2-(1H)-pyridone；5-methyl-1-naphthalen-1-ylpyridin-2-one
• CAS: 53427-82-0
• 化学式: C₁₆H₁₃NO
• 分子量: 235.285
• InChiKey: QXUFUYWNOKGTOA-UHFFFAOYSA-N

物化性质

• 沸点：
  429.0±18.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-羟基-5-甲基嘧啶 、 1-碘萘 以68%的产率得到5-methyl-1-(1'-naphthyl)-2(1H)pyridone
  参考文献：
  名称：

  5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use

  摘要：

  描述了一种含有活性成分5-甲基-1-苯基-2-(1H)-吡啶酮的新型镇痛、退烧、抗炎组合物。这种组合物还被发现能显著降低血清尿酸和葡萄糖水平，并对人类和其他哺乳动物的多种上呼吸道疾病治疗有效。皮肤状况如皮炎和毒葛也可以通过这种药物缓解。含有5-甲基-1-苯基-2-(1H)-吡啶酮的组合物在口服时不引起刺激，在应用于特定靶组织时也没有显著的刺激或其他后遗症。

  公开号：

  US03974281A1

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• Method for reducing serum glucose levels
  申请人：Affiliated Medical Research, Inc.

  公开号：US04042699A1

  公开（公告）日：1977-08-16

  Novel pharmaceutical compositions containing as the active ingredient the compound 5-methyl-1-phenyl-2-(1H)-pyridone are described. Such compositions have been found to have a metabolic property which causes significant lowering of serum glucose levels in humans and other mammals. The compositions containing 5-methyl-1-phenyl-2-(1H)-pyridone caused no irritation on oral administration or when applied to specific target tissues showed no significant irritation or other sequelae.

  本发明涉及一种含有化合物5-甲基-1-苯基-2-(1H)-吡啶酮作为活性成分的新型药物组合物。发现这种组合物具有代谢特性，可以显著降低人类和其他哺乳动物的血清葡萄糖水平。含有5-甲基-1-苯基-2-(1H)-吡啶酮的组合物在口服时不引起刺激，在应用于特定目标组织时也没有显著的刺激或其他后遗症。
• MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
  申请人：BLATT LAWRENCE M.

  公开号：US20090286843A1

  公开（公告）日：2009-11-19

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合物在内的组合物。该实施例还提供了治疗方法，包括治疗黄热病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述化合物或组合物的有效量。
• Aerosol pirfenidone and pyridone analog compounds and uses thereof
  申请人：Avalyn Pharma Inc.

  公开号：US10028966B2

  公开（公告）日：2018-07-24

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

  本文公开了用于气雾化的吡非尼酮或吡啶酮类似物化合物制剂，以及使用此类制剂气雾给药吡非尼酮或吡啶酮类似物化合物以预防或治疗各种纤维化和炎症性疾病，包括与肺、心、肾、肝、眼和中枢神经系统有关的疾病。在某些实施方案中，本文所述的吡非尼酮或吡啶酮类似化合物制剂和给药方案可实现吡非尼酮或吡啶酮类似化合物的有效局部给药。组合物包括本文所述的所有制剂、试剂盒和装置组合。方法包括用于生产和使用所述组合物的吸入程序、适应症和生产工艺。
• Aerosol pirfenidone and pyridone analog compound and uses thereof
  申请人：Avalyn Pharma Inc.

  公开号：US11071741B2

  公开（公告）日：2021-07-27

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

  本文公开了用于气雾化的吡非尼酮或吡啶酮类似物化合物制剂，以及使用此类制剂气雾给药吡非尼酮或吡啶酮类似物化合物以预防或治疗各种纤维化和炎症性疾病，包括与肺、心、肾、肝、眼和中枢神经系统有关的疾病。在某些实施方案中，本文所述的吡非尼酮或吡啶酮类似化合物制剂和给药方案可实现吡非尼酮或吡啶酮类似化合物的有效局部给药。组合物包括本文所述的所有制剂、试剂盒和装置组合。方法包括用于生产和使用所述组合物的吸入程序、适应症和生产工艺。